Quan Capital — 2021 Investments
3 investments dated 2021 · listed companies and verified rows first · show all
Design Therapeutics is a biopharmaceutical company developing small molecule therapeutic candidates for serious genetic diseases through its GeneTAC (Gene Targeted Chimera) platform.
BiotechMedical DevicesSolana Beach, US
Pratik Shah, Ph.D.(Executive Officer, Director)Aseem Z. Ansari, Ph.D.(Director)Sean Jeffries, Ph.D.(Executive Officer)
BoardSimeon George, M.D.(Director)Stella Xu, Ph.D.(Director)Rodney Lappe, Ph.D.(Director)
Co-investorsAvoro Capital AdvisorsRA CapitalSR One Capital ManagementWellington ManagementWestRiver Group
An innovative biopharmaceutical company focused on developing therapies for chronic kidney disease across multiple clinical stages, with a pipeline of eight products covering conditions such as hyperphosphatemia, renal anemia, IgA nephropathy, and diabetic kidney disease.
BiotechDigital HealthHealthtechMedical DevicesShanghai, CN
Co-investorsLAVLilly Asia Ventures3E Bioventures Capital3H Health InvestmentSherpa Healthcare PartnersYuanBio Venture Capital
BiotechPhiladelphia, US
Philip R. Johnson, M.D.(Executive Officer, Director)inDora Mitchell(Executive Officer)Lori Forrest(Executive Officer)Leon Moulder, Jr.(Director)Benjamin Lund(Director)in
BoardTomas Kiselak(Director)
Co-investorsAgent CapitalDC Investment PartnersLongwood FundOUP (Osage University Partners)Pfizer Venture InvestmentsBain Capital Life Sciences+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.














